Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,854.78 +938.52 (+1.40%) CMC Crypto 200
1,371.82 +41.21 (+3.10%)
Ionis Pharmaceuticals, Inc. (IONS)
After hours:
| Previous close | 51.86 |
| Open | 52.34 |
| Bid | 51.40 x 400 |
| Ask | 51.47 x 200 |
| Day's range | 51.05 - 52.34 |
| 52-week range | 35.95 - 54.44 |
| Volume | |
| Avg. volume | 1,341,416 |
| Market cap | 7.51B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 60.45 |
ZacksIonis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIonis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.
PR NewswireIonis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS) demonstrating consistent and encouraging clinical improvement on measures assessing all functional domains including communication, cognition and motor function. Overall, 97% of people in the medium and high dose groups saw an improvement in overall AS symptoms as measured by the Symp
